Bicalutamide

Bicalutamide is a member of the nonsteroidal antiandrogen (NSAA) class, a group of drugs that oppose androgen action without themselves being steroids ^[1]. It is a competitive, so-called silent antagonist of the androgen receptor, meaning it occupies the receptor and stops the natural androgens testosterone and dihydrotestosterone from binding, while producing essentially no activating effect of its own ^[4]. The medicine is a racemic mixture of two mirror-image forms, but almost all of its antiandrogen activity comes from the (R)-enantiomer, which is cleared slowly and builds up in the blood during daily use ^[1]. It does not block the enzyme 5-alpha-reductase and does not interfere with androgen production ^[1].

The principal use of bicalutamide is in prostate cancer, a hormone-driven disease whose growth depends on androgens. In advanced or metastatic disease it is combined with a gonadotropin-releasing hormone analogue or with surgical castration, a strategy known as combined androgen blockade, where it counters the temporary surge in testosterone that these treatments can provoke ^[1]. In several countries a higher dose is licensed as monotherapy for localized or locally advanced nonmetastatic cancer, either alone or as an addition to surgery or radiotherapy ^[2]. Beyond cancer, bicalutamide has been used off-label in situations that call for androgen blockade, such as feminizing hormone therapy and certain skin and hair conditions, though these uses are not among its approved indications.

Bicalutamide has been studied extensively, most notably in the large Early Prostate Cancer (EPC) programme, which examined its use as monotherapy and as an addition to standard treatment ^[2]. This research helped define both its benefits and its limits; in men with lower-risk early disease, adding the drug did not clearly improve survival and could even be counterproductive, whereas patients with more advanced disease tended to benefit more ^[2]. It has also served as a reference compound in the development of newer, more potent antiandrogens such as enzalutamide, which were designed to remain effective once prostate cancer becomes resistant to castration and to bicalutamide itself ^[3]. That resistance is thought to involve changes in the androgen receptor, and unlike some older antiandrogens, bicalutamide generally does not switch to stimulating mutated receptors ^[4].

Pharmacologically, bicalutamide is well absorbed by mouth, is not affected by food, and has a notably long duration of action, so it is taken only once a day ^[1]. It is broken down mainly in the liver and is eliminated roughly equally in the urine and the feces ^[1]. Because blocking the androgen receptor removes feedback signals in men, monotherapy tends to raise circulating testosterone and estrogen, which explains why breast-related effects are common with the single-agent regimen ^[1][2].

Bicalutamide was developed by the pharmaceutical company ICI, later AstraZeneca, and reached the market in the mid-1990s under the brand name Casodex ^[1]. It is approved in many countries, is included on the World Health Organization's Model List of Essential Medicines, and is now widely sold as an inexpensive generic. It is supplied as oral tablets and is a prescription-only medicine. Because it can harm a developing fetus, it is not used in pregnancy.

Bicalutamide is prescription only. The most common effects are breast tenderness and breast growth (gynecomastia), hot flashes, and fatigue, all reflecting reduced androgen signaling. It can cause liver injury, so liver function is checked before and during treatment, and it is stopped if serious liver problems appear. Other effects include reduced libido, and when used as monotherapy it tends to preserve erectile function and bone density better than full testosterone suppression. It carries a small risk of lung inflammation (interstitial lung disease). It can increase the effect of blood thinners like warfarin. It is not intended for use in women who are or may become pregnant.

Bicalutamide is metabolized by CYP3A4 and has been shown to inhibit this enzyme in vitro; however, clinical studies using midazolam as a CYP3A4 probe found no clinically relevant inhibition at the standard 150 mg dose (pharmacokinetic interaction absent in vivo despite in vitro evidence) ^[1]. The drug does not induce hepatic enzyme systems at doses of 150 mg or less in humans. Interactions with other medications remain largely unexplored; most concurrent drugs have not been formally studied with bicalutamide.

Checking a whole stack? Run it through interactions + stacks.

Bicalutamide was developed by the pharmaceutical company ICI, later Zeneca and then AstraZeneca, as part of the nonsteroidal antiandrogen class that began with flutamide and nilutamide. It was designed for improved tolerability and convenient once-daily dosing, and its activity resides in the R-enantiomer of the molecule. The drug received United States approval in 1995 under the brand name Casodex for use in advanced prostate cancer combined with medical or surgical castration. It has since become a widely used generic and is included on the World Health Organization's List of Essential Medicines.

Bicalutamide is often described as the workhorse of the nonsteroidal antiandrogens, favored for a generally more tolerable profile and simpler dosing than its predecessors. It earned a solid reputation by blocking androgen signaling without lowering the body's testosterone production, which for some patients preserves aspects of quality of life. Oncologists value it both as part of combined androgen blockade and, at higher doses, as a single agent option in appropriately selected earlier disease. Its inclusion among essential medicines reflects broad, durable clinical acceptance, tempered by awareness of side effects such as breast tenderness and enlargement.